Colestipol Clofibrate

Colestyramine does not alter the pharmacokinetics of clofibrate when both drugs are given at the same time. Similarly colestipol does not alter the pharmacokinetics of clofibrate or fenofibrate, and colesevelam does not alter the pharmacokinetics of fenofibrate. Colestipol can reduce the absorption of gemfibrozil if given at the same time, but not if administration is separated by 2 hours. A similar interaction occurs between bezafibrate and colestyramine... 

Over a 6-day period no clinically relevant changes in the pharmacokinetics of clofibrate occurred in24 healthy subjects, who were given daily doses of colestipol 10 g at the same time as clofibrate 500 mg. Colestyramine 4 g four times daily had no effect on the fasting plasma levels, urinary and faecal excretion, or the half-life of clofibrate in 6 patients taking 1 g of clofibrate twice daily. In this study, the morning and evening doses of colestyramine were taken at the same time as the clofibrate. ... 

DeSante KA, DiSante AR, Albert KS, Weber DJ, Welch RD, Vecchio TJ. The effect of colestipol hydrochloride on the bioavailabihty and pharmacokinetics of clofibrate. J Clin... 

Colestipol was well tolerated and reduced plasma cholesterol levels during a 2 year study in types II, III and IV hyperlipoproteinemic subjects.In another study, colestipol, at a daily dose of 15 g, decreased plasma cholesterol levels in type II and IV subjects. The addition of clofibrate further reduced cholesterol values. Serum triglyceride levels were elevated by colestipol but the effect could be reversed by clofibrate.61 Similar triglyceride elevations have been observed with cholestyramlne62 which, during the past year received FDA approval for a lipid-lowering indication. 

Rose et al. have examined the possibility of combining clofibrate treatment and the use of colestipol resin, primarily in order to improve the effects on low-density Upopro-tein (which during clofibrate therapy is of-... 

Rose, H. G., Haft, G. K. and Juliano, J. (1976) Clofibrate-induced low density lipoprotein elevation therapeutic implications and treatment by colestipol resin. Atherosclerosis, 23, 413. 

---